Advil Tablets 200mg (Haleon) – Illegible Label (2022)
Class I: A situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death
Class I recall indicates potential for serious health consequences.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
Advil (ibuprofen) Tablets, 200 mg, packaged as a) 360-count bottles (UPC 3 0573 0154 60 4), and b) 200-count bottles (UPC 3 0573 0154 21 5), Pfizer, Madison, NJ 07940
Brand
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon
Lot Codes / Batch Numbers
a) Lots EJ2218, EJ2219, EJ2220, Exp 09/2023, b) Lot 953D, Exp 05/2025
Products Sold
a) Lots EJ2218, EJ2219, EJ2220, Exp 09/2023; b) Lot 953D, Exp 05/2025
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon is recalling Advil (ibuprofen) Tablets, 200 mg, packaged as a) 360-count bottles (UPC 3 0573 0154 60 4), and b) 2 due to Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back. This is a Class I recall, indicating a high risk of serious health consequences. Based on FDA drug enforcement report.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back
Recommended Action
Per FDA guidance
Consumers should stop using the product and contact the recalling firm, their healthcare provider, or return it to the place of purchase.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 7, 2026